Liposomal irinotecan (ONIVYDE®) + 5-FU/LV is the only Category 1 NCCN chemotherapy recommendation for patients with post-gemcitabine metastatic pancreatic cancer with good performance status and disease progression3†
Tumor type
Line of therapy
NCCN recommendation
NCCN Category
Metastatic pancreatic cancer
Second-line, with previous gemcitabine-based therapy
5-FU/LV + liposomal irinotecan for patients with metastatic pancreatic cancer who have a good performance status†
*Therapies are categorized based on National Comprehensive Cancer Network (NCCN) categories of evidence and consensus, which are defined as follows: 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.3
†Good performance status is defined as ECOG 0-1, with good biliary drainage and adequate nutritional intake.3
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
*Therapies are categorized based on National Comprehensive Cancer Network (NCCN) categories of evidence and consensus, which are defined as follows: 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. All recommendations are category 2A unless otherwise noted.3
†Good performance status is defined as ECOG 0-1, with good biliary drainage and adequate nutritional intake.3
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
YOU ARE NOW LEAVING ONIVYDE.COM
You are about to leave ONIVYDE.com and visit a third-party website. The website will load automatically unless you click Cancel.
